Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082907 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2AFBP1ALDH1A1 | |
| SCHEMBL10669864 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10669860 | 0.87 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2081608 | 0.85 | MAPT (0.53) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2081607 | 0.85 | MAPT (0.53) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL15163803 | 0.83 | JUN (0.59) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12784443 | 0.82 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2079001 | 0.82 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2079003 | 0.82 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12784329 | 0.81 | MAOB (0.49) | MAPTMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1973877-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | MAPT 1582/4885MEN1 4042/4885KMT2A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.